MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41392-024-01865-6

Медицинская библиотека · Signal transduction and targeted therapy · 2024

Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.

Chen Xiaozhong, Wang Wei, Zou Qingfeng, Zhu Xiaodong, Lin Qin, Jiang Yi, Sun Yan, Shen Liangfang, Wang Lin, Zou Guorong, Lin Xiaoyan, Lin Shaojun, Li Minying, Wang Ying, Xu Ruilian, Ao Rui, Wang Rensheng, Lin Haifeng, Huang Shuang, Xu Tingting, Li Wenting, Xia Mengying, Xia Yu, Wang Zhongmin, Li Baiyong, Li Jingao, Hu Chaosu

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

Penpulimab is an anti-programmed cell death-1 (PD-1) IgG1 antibody with no Fc gamma receptor (FcγR) binding activity, and thus theoretically reduced immune-related adverse events (irAEs) while maintaining efficacy. This single-arm, phase II trial conducted across 20 tertiary care centers in China enrolled adult patients with metastatic nasopharyngeal carcinoma (NPC) who had failed two or more lines of previous systemic chemotherapy. Patients received 200-mg penpulimab intravenously every 2 weeks (4 weeks per cycle) until disease progression or intolerable toxicities. The primary endpoint was objective response rate (ORR) per RECIST (version 1.1), as assessed by an independent radiological review committee. The secondary endpoints included progression-free survival (PFS) and overall survival (OS). One hundred thirty patients were enrolled and 125 were efficacy evaluable. At the data cutoff date (September 28, 2022), 1 patient achieved complete response and 34 patients attained partial response. The ORR was 28.0% (95% CI 20.3-36.7%). The response was durable, with 66.8% still in response at 9 months. Thirty-three patients (26.4%) were still on treatment. The median PFS and OS were 3.6 months (95% CI = 1.9-7.3 months) and 22.8 months (95% CI = 17.1 months to not reached), respectively. Ten (7.6%) patients experienced grade 3 or higher irAEs. Penpulimab has promising anti-tumor activities and acceptable toxicities in heavily pretreated metastatic NPC patients, supporting further clinical development as third-line treatment of metastatic NPC.

Для цитирования: Chen Xiaozhong, Wang Wei, Zou Qingfeng, Zhu Xiaodong, Lin Qin, Jiang Yi, Sun Yan, Shen Liangfang, Wang Lin, Zou Guorong, Lin Xiaoyan, Lin Shaojun, Li Minying, Wang Ying, Xu Ruilian, Ao Rui, Wang Rensheng, Lin Haifeng, Huang Shuang, Xu Tingting, Li Wenting, Xia Mengying, Xia Yu, Wang Zhongmin, Li Baiyong, Li Jingao, Hu Chaosu. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.. Signal transduction and targeted therapy. 2024. DOI: 10.1038/s41392-024-01865-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.